Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Clinical & experimental metastasis - 1 Jan 2004

Hiscox Stephen, Morgan Liam, Barrow Denise, Dutkowskil Carol, Wakeling Alan, Nicholson Robert I

Abstract excerpt

Despite an initial response to antihormonal therapies, the development of resistance will occur in a significant number of breast cancer patients. The mechanisms that underlie acquired resistance are not yet clear. Using a previously established in vitro cell model of tamoxifen resistance in MCF7 cells, shown to display autocrine epidermal growth factor receptor (EGFR) signalling, we assessed how resistance might...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Cell Adhesion

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gefitinib

Share to Microscopy, Fluorescence

Share to Neoplasm Invasiveness

Share to Quinazolines

Share to Tamoxifen

Source

Identifiers

PMID: 15387370
DOI: 10.1023/b:clin.0000037697.76011.1d

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).PMID 15387370Read ↗

Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.Semantic proximity Read ↗

Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.Semantic proximity Read ↗

Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells.Semantic proximity Read ↗

Tamoxifen metabolites treatment promotes ERα+ transition to triple negative phenotype in vitro, effects of LDL in chemoresistance.Semantic proximity Read ↗

A mechanism of drug resistance to tamoxifen in breast cancer.Semantic proximity Read ↗

Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.Semantic proximity Read ↗

ROCK signaling mediates the adoption of different modes of migration and invasion in human mammary epithelial tumor cells.Semantic proximity Read ↗

Epithelial membrane protein-1 is a biomarker of gefitinib resistance.Semantic proximity Read ↗

Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells.Semantic proximity Read ↗

The process of malignant progression in human breast cancer.Semantic proximity Read ↗

Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.Semantic proximity Read ↗

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.